TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21251991

Group type: EXPERIMENTAL
Intervention: Collagen hydrolysate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18296964

Group type: EXPERIMENTAL
Intervention: Low velocity resistance training (LV)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Traditional strength (TS)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Traditional endurance (TE)
Number of subjects: 34
Study: 16253975

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily) for 6 months
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 37
Study: 12693807

Group type: EXPERIMENTAL
Intervention: Rifampicin plus ethambutol
Number of subjects: 42

Group type: COMPARATOR
Intervention: Rifampicin, ethambutol and isoniazid
Number of subjects: 42
Study: 10991886

Group type: EXPERIMENTAL
Intervention: Praziquantel (1,800 mg) with high-lipid diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Praziquantel (1,800 mg) with high-carbohydrate diet
Number of subjects: 0
Study: 8667160

Group type: EXPERIMENTAL
Intervention: Directed-thinking tasks to manipulate the salience of desirable self-characteristics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Directed-thinking tasks to manipulate the salience of undesirable self-characteristics
Number of subjects: 0
Study: 1587429

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa‐2b
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa‐2b with prednisone priming
Number of subjects: 115
Study: 3898905

Group type: EXPERIMENTAL
Intervention: Intranasal flunisolide 50 micrograms per nostril b.i.d.
Number of subjects: 99

Group type: COMPARATOR
Intervention: Oral flunisolide 500 micrograms b.i.d.
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (intranasal and oral) b.i.d.
Number of subjects: 99
Study: 31276193

Group type: EXPERIMENTAL
Intervention: IV fluid restriction
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Standard care (IV fluid therapy)
Number of subjects: 1554
Study: 29696659

Group type: EXPERIMENTAL
Intervention: Latent factor mixed models (LFMMs)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Moran spectral outlier detection/randomization (MSOD‐MSR)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Candidate SNPs identified through LFMMs and MSOD‐MSR
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Genes tagged by candidate loci associated with drought and salinity
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Genes tagged by candidates associated with soil nitrogen and atmospheric nitrogen
Number of subjects: 202
Study: 26562755

Group type: EXPERIMENTAL
Intervention: 5‐week endurance exercise program (three cycle ergometer sessions per week)
Number of subjects: 33
Study: 25125506

Group type: EXPERIMENTAL
Intervention: Methazolamide (40 mg b.i.d.)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 23299270

Group type: EXPERIMENTAL
Intervention: Silicone gel sheets applied to half of the scar for 6 months
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Silicone gel sheets
Number of subjects: 10

Group type: COMPARATOR
Intervention: Untreated scar sides
Number of subjects: 10
Study: 20708858

Group type: EXPERIMENTAL
Intervention: Threat condition (believing they ingested 500 mg of disulfiram)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral condition (believing they ingested a placebo)
Number of subjects: 0
Study: 18374395

Group type: EXPERIMENTAL
Intervention: Spanner (temporary prostatic stent)
Number of subjects: 186
Study: 16208302

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion sessions (10 sessions, twice a week for 5 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: AcupunctureSham (10 sessions, twice a week for 5 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study: 12654073

Group type: EXPERIMENTAL
Intervention: Sensory integrative therapy (n=15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Vestibular stimulation in addition to sensory integrative therapy (n=15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental therapy (n=15)
Number of subjects: 45
Study: 10477025

Group type: EXPERIMENTAL
Intervention: Video-based patient positioning system
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional treatment room lasers
Number of subjects: 11
Study: 8735995

Group type: EXPERIMENTAL
Intervention: High contextual interference (serial condition)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low contextual interference (blocked condition)
Number of subjects: 24
Study: 8394538

Group type: EXPERIMENTAL
Intervention: Azathioprine (Aza) and Prednisolone (P), n = 54
Number of subjects: 195

Group type: COMPARATOR
Intervention: Cyclosporin (CsA) and Prednisolone (P), n = 58
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Triple therapy of Aza-CsA-P, n = 41
Number of subjects: 195

Group type: COMPARATOR
Intervention: Conventional therapy of Aza-P, n = 42
Number of subjects: 195

Group type: COMPARATOR
Intervention: Conventional immunotherapy
Number of subjects: 195
Study: 3013772

Group type: EXPERIMENTAL
Intervention: Low-sodium diet (40 mmol per day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-sodium diet (300 mmol per day)
Number of subjects: 10
Study: 29378416

Group type: EXPERIMENTAL
Intervention: In-person training
Number of subjects: 131

Group type: COMPARATOR
Intervention: Online training
Number of subjects: 131
Study: 27196093

Group type: EXPERIMENTAL
Intervention: HPV vaccine multilevel intervention (MLI)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Influenza vaccine multilevel intervention (comparison group)
Number of subjects: 337
Study: 23625461

Group type: EXPERIMENTAL
Intervention: Lengthened position (LL, 40‐90° knee flexion)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Shortened position (SL, 0‐50° knee flexion)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Detraining effects in SL
Number of subjects: 31
Study: 22948897

Group type: EXPERIMENTAL
Intervention: Safinamide 100 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Safinamide 350 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selegiline 10 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenelzine 30 mg/day
Number of subjects: 0
Study: 20004013

Group type: EXPERIMENTAL
Intervention: 50 IU oxytocin (n=292)
Number of subjects: 577

Group type: COMPARATOR
Intervention: 5 mL water (placebo) (n=285)
Number of subjects: 577
Study: 18203329

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (DMARD therapy)
Number of subjects: 22
Study: 16848175

Group type: EXPERIMENTAL
Intervention: Betahistine mesilate and Flunarizine Hydrochloride
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vitamin B6 and Flunarizine Hydrochloride
Number of subjects: 60
Study: 14602541

Group type: EXPERIMENTAL
Intervention: Qigong (10 weeks)
Number of subjects: 58
Study: 10448261

Group type: EXPERIMENTAL
Intervention: Letrozole 0.5 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg
Number of subjects: 46
Study: 7919590

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 4500

Group type: COMPARATOR
Intervention: No calcium blocker
Number of subjects: 4500
Study: 2689018

Group type: EXPERIMENTAL
Intervention: Amorolfine cream 0.5%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bifonazole cream 1%
Number of subjects: 40
Study: 788464

Group type: EXPERIMENTAL
Intervention: Long-acting amitriptyline (Diffucaps) 25 mg at evening meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ordinary amitriptyline 40 mg at bedtime
Number of subjects: 0
Study: 31557067

Group type: EXPERIMENTAL
Intervention: Complete lymph node dissection (CLND)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 483
Study: 28556506

Group type: EXPERIMENTAL
Intervention: Fosdagrocorat 5 mg
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Fosdagrocorat 10 mg
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Fosdagrocorat 15 mg
Number of subjects: 323

Group type: COMPARATOR
Intervention: Prednisone 5 mg
Number of subjects: 323

Group type: COMPARATOR
Intervention: Prednisone 10 mg
Number of subjects: 323
Study: 25460344

Group type: EXPERIMENTAL
Intervention: Telephone-mediated program combining problem solving training (PST) with modules for depression, anxiety, insomnia, and headache.
Number of subjects: 0
Study: 23870174

Group type: EXPERIMENTAL
Intervention: Argan oil (25 mL/day for 3 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Butter (control group)
Number of subjects: 39
Study: 21585288

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg p.o. (positive control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg/day p.o. for 14 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Roflumilast 1000 μg/day p.o. for 14 days
Number of subjects: 80
Study: 18263674

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 16816559

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral adherence intervention
Number of subjects: 230

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 230
Study: 12735570

Group type: EXPERIMENTAL
Intervention: Fresh-frozen plasma
Number of subjects: 56

Group type: COMPARATOR
Intervention: Albumin 5%
Number of subjects: 56
Study: 11068941

Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9313729

Group type: EXPERIMENTAL
Intervention: 2 mm axial spiral CT protocol
Number of subjects: 35

Group type: COMPARATOR
Intervention: 10 mm axial spiral CT protocol
Number of subjects: 35
Study: 7953259

Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg per rectum
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pethidine 50 mg intravenously
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pethidine with intravenous benzodiazepines
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diclofenac or pethidine alone
Number of subjects: 60
Study: 2441163

Group type: EXPERIMENTAL
Intervention: Caffeine alone, 250 mg intravenously (i.v.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adenosine alone, increasing dose of 0.04‐0.16 mg/kg/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adenosine infusion after caffeine
Number of subjects: 10
Study: 31404005

Group type: EXPERIMENTAL
Intervention: Hybrid minimally invasive esophagectomy (HMIE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open esophagectomy (OE)
Number of subjects: 0
Study: 30151409

Group type: EXPERIMENTAL
Intervention: Azithromycin (single dose every 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (single dose every 6 months)
Number of subjects: 0
Study: 28216062

Group type: EXPERIMENTAL
Intervention: Nalmefene (18 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 26242149

Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine treatment (anastrozole, exemestane)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (doxorubicin plus paclitaxel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with trastuzumab
Number of subjects: 0
Study: 23108194

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg daily for 60 days
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 20530282

Group type: EXPERIMENTAL
Intervention: IROX (irinotecan + oxaliplatin)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: FOLFOX (fluorouracil + oxaliplatin)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: IFL (fluorouracil + irinotecan)
Number of subjects: 520
Study: 18222261

Group type: EXPERIMENTAL
Intervention: CO2 insufflation (group I, n = 39)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Unprotected controls (group II, n = 41)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CO2 insufflation (group I)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Unprotected controls (group II)
Number of subjects: 80
Study: 16857131

Group type: EXPERIMENTAL
Intervention: Ultrathin flap LASIK
Number of subjects: 42

Group type: COMPARATOR
Intervention: LASEK
Number of subjects: 42
Study: 14664876

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 microg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Vaginal misoprostol
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study: 10809397

Group type: EXPERIMENTAL
Intervention: Remineralizing solution only (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 35% phosphoric acid etching for 30 s + remineralizing solution (Group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remineralizing solution + daily fluoride toothpaste slurry (1,000 ppm for 5 min) (Group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 35% phosphoric acid etching + daily fluoride treatment (Group D)
Number of subjects: 0
Study: 14688950

Group type: EXPERIMENTAL
Intervention: Special preterm formula
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Modified formula
Number of subjects: 70

Group type: COMPARATOR
Intervention: Preterm formula
Number of subjects: 70
Study: 1354432

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 0.1 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 0.2 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 0.2 g with Maalox 70 (10 ml 2h and 10 ml 15 min before)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 0.2 g with famotidine (40 mg 1h before)
Number of subjects: 10
Study: 6896649

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.2 mg kg‐1 in 10% dextrose solution)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Extradural morphine (0.2 mg kg‐1 in 0.9% saline)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intramuscular morphine (0.2 mg kg‐1 in 0.9% saline)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study: 31194778

Group type: COMPARATOR
Intervention: Oral treatments (risperidone, olanzapine)
Number of subjects: 12232

Group type: EXPERIMENTAL
Intervention: Long-acting injectables (risperidone long acting, paliperidone long acting)
Number of subjects: 12232

Group type: COMPARATOR
Intervention: Oral treatments (clozapine, olanzapine)
Number of subjects: 12232

Group type: EXPERIMENTAL
Intervention: Long-acting injectables
Number of subjects: 12232

Group type: EXPERIMENTAL
Intervention: Long-acting treatment switched from another long-acting
Number of subjects: 12232
Study: 29701875

Group type: EXPERIMENTAL
Intervention: Optimal surrogate based on super-learner and targeted super-learner estimators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermediate time point candidate surrogate outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment (dengue vaccine)
Number of subjects: 0
Study: 26547659

Group type: EXPERIMENTAL
Intervention: 0.3% rhFGF‐2
Number of subjects: 328
Study: 24187095

Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 449
Study: 21745060

Group type: EXPERIMENTAL
Intervention: Group size of 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group size of 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group size of 4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 19840650

Group type: EXPERIMENTAL
Intervention: 17% EDTA + 2.5% NaOCl (n = 30)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 7% maleic acid + 2.5% NaOCl (n = 30)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.9% saline (n = 20)
Number of subjects: 80
Study: 17057048

Group type: EXPERIMENTAL
Intervention: Full-dose TIV (n = 222)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Half-dose TIV (n = 222)
Number of subjects: 444
Study: 15588236

Group type: EXPERIMENTAL
Intervention: Cortisol replacement (A)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (B)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 15
Study: 10908094

Group type: EXPERIMENTAL
Intervention: β-blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9240642

Group type: EXPERIMENTAL
Intervention: Postoperative inguinofemoral radiation therapy (Group 1, 65 patients)
Number of subjects: 135

Group type: COMPARATOR
Intervention: No inguinofemoral radiation therapy (Group 2, 70 patients)
Number of subjects: 135
Study: 8252455

Group type: EXPERIMENTAL
Intervention: Aminophylline (2 mg/kg, i.v.)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 52
Study: 3535686

Group type: EXPERIMENTAL
Intervention: Active slow release theophylline (Slo‐phyllin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo slow release theophylline
Number of subjects: 0
Study: 31758195

Group type: COMPARATOR
Intervention: Colistin monotherapy
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Colistin-meropenem combination therapy
Number of subjects: 214
Study: 30671682

Group type: EXPERIMENTAL
Intervention: Game Plan (GP) plus standard post-test counseling (SPC)
Number of subjects: 40
Study: 28292338

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (CH) paste
Number of subjects: 40

Group type: COMPARATOR
Intervention: Calcium hydroxide (CH) paste plus 1.0 percent chlorhexidine (CHX)
Number of subjects: 40
Study: 25712760

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri Prodentis (one tablet every 24 hours for 30 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (administered after probiotic treatment for 6 months)
Number of subjects: 34
Study: 24449961

Group type: COMPARATOR
Intervention: No Testimonial Group
Number of subjects: 5498

Group type: EXPERIMENTAL
Intervention: Unaffiliated Testimonial Group
Number of subjects: 5498

Group type: EXPERIMENTAL
Intervention: Affiliated Testimonial Group
Number of subjects: 5498
Study: 21771281

Group type: EXPERIMENTAL
Intervention: Vardenafil (starting dose 10 mg, titratable to 5 mg or 20 mg after 4 weeks)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 19811584

Group type: EXPERIMENTAL
Intervention: Powered toothbrush
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 60
Study: 16923005

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) in patients with prior RVAP (Group A)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy (CRT) in patients without prior RVAP (Group B)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Echocardiographic response to CRT in patients with prior RVAP (Group A)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Echocardiographic response to CRT in patients without prior RVAP (Group B)
Number of subjects: 98
Study: 14698860

Group type: EXPERIMENTAL
Intervention: High doses of methylprednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 11742338

Group type: EXPERIMENTAL
Intervention: Identification of the external branch of the superior laryngeal nerve (EBSLN) in group A (137 patients) with superior thyroid artery ligation after identification of EBSLN.
Number of subjects: 289

Group type: COMPARATOR
Intervention: Surgical approach in group B (152 patients) with separate ligation of the superior thyroid artery's branches close to the gland.
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Phoniatric evaluation with videostrobolaryngoscopy and spectrographic examination in both groups.
Number of subjects: 289
Study: 9280170

Group type: EXPERIMENTAL
Intervention: High-carbohydrate, low-fat (HC) diet
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-fat, low-carbohydrate (HF) diet
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 11
Study: 8339033

Group type: EXPERIMENTAL
Intervention: Auriculo‐acupuncture plus needle embedding in Heart acupoint
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (non-point)
Number of subjects: 12
Study: 3524436

Group type: EXPERIMENTAL
Intervention: BW942C
Number of subjects: 134

Group type: COMPARATOR
Intervention: TMP-SMX
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Combination of BW942C and TMP-SMX
Number of subjects: 134
Study: 31903980

Group type: EXPERIMENTAL
Intervention: Mechanical bed massage
Number of subjects: 28

Group type: COMPARATOR
Intervention: Resting (control group)
Number of subjects: 28
Study: 29370942

Group type: EXPERIMENTAL
Intervention: Maintaining apical patency (AP)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Nonapical patency (NAP)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Analgesic consumption
Number of subjects: 320
Study: 27663256

Group type: EXPERIMENTAL
Intervention: WIC Fresh Start (WFS) nutrition education intervention
Number of subjects: 744

Group type: COMPARATOR
Intervention: Control group (WIC participants nationwide)
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Measures developed for the study
Number of subjects: 744
Study: 24108237

Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg/day)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg/day)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Control (Amlodipine monotherapy)
Number of subjects: 282
Study: 22287494

Group type: EXPERIMENTAL
Intervention: β‐TCP
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PRP/β‐TCP
Number of subjects: 14
Study: 20332721

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) injection in triceps surae muscles
Number of subjects: 22

Group type: COMPARATOR
Intervention: Phenol nerve block of the tibialis posterior nerve
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 22
Study: 18164245

Group type: EXPERIMENTAL
Intervention: Nolomirole (5 mg b.i.d.)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Nolomirole
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Nolomirole and Placebo
Number of subjects: 1000